First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) - Total Assets
Based on the latest financial reports, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV) holds total assets worth $290.58 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Total Assets Trend (2023–2024)
This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's total assets have evolved over time, based on quarterly financial data. Also see First Tracks Biotherapeutics, Inc. Ordin (TRAXV) market capitalisation for the company's overall valuation and market capitalisation.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Asset Composition Analysis
Current Asset Composition (December 2024)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's total assets of $290.58 Million consist of 88.2% current assets and 11.8% non-current assets. Review TRAXV liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2024)
This chart illustrates how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest First Tracks Biotherapeutics, Inc. Ordin stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's current assets represent 88.2% of total assets in 2024, a decrease from 89.7% in 2023.
- Cash Position: Cash and equivalents constituted 27.9% of total assets in 2024, up from 8.1% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Competitors by Total Assets
Key competitors of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.74 | - | - |
| Quick Ratio | 8.74 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $256.29 Million | - | - |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued - Advanced Valuation Insights
This section examines the relationship between First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 1.39 |
| Asset Growth Rate (YoY) | -0.5% |
| Total Assets | $441.89 Million |
| Market Capitalization | $613.49 Million USD |
Valuation Analysis
Above Book Valuation: The market values First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's assets above their book value (1.39x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's assets decreased by 0.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (2023–2024)
The table below shows the annual total assets of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued from 2023 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $441.89 Million | -0.50% |
| 2023-12-31 | $444.11 Million | -- |
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more